Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean aromatase inhibitor?
Displaying drugs 26 - 50 of 2428 in total

Memantine

Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's...
Approved
Investigational
Matched Description: … Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors …
Matched Categories: … Cholinesterase Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …

Thrombin

Also known as coagulation factor II, thrombin is a serine protease that plays a physiological role in regulating hemostasis and maintaining blood coagulation. Once converted from prothrombin, thrombin converts fibrinogen to fibrin, which, in combination with platelets from the blood, forms a clot. Medical thrombin is a protein substance produced...
Approved
Investigational

Moxonidine

Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown...
Approved
Investigational
Matched Description: … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors …

Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, …
Matched Categories: … OCT1 inhibitors ... OCT2 Inhibitors ... DPP-IV Inhibitors ... Enzyme Inhibitors ... Protease Inhibitors …

Pralsetinib

Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific RET RTK inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... MATE inhibitors ... BSEP/ABCB11 Inhibitors ... MATE 1 Inhibitors ... MATE 2 Inhibitors …

Durlobactam

Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases. The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... beta-Lactamase Inhibitors …

Hexocyclium

Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the...
Approved
Matched Description: … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced …

Tivozanib

Renal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed to treat adult patients with relapsed or...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Receptors, Vascular Endothelial Growth Factor, antagonists & inhibitors …

Relebactam

Relebactam is a diazabicyclooctane beta-lactamase inhibitor, similar in structure to avibactam.[A181195,A181207] It includes a piperidine ring which reduces export from bacterial cells by producing a positive charge. It is currently available in a combination product which includes imipenem and cilastatin to treat complicated urinary tract infections (UTIs), pyelonephritis, and complicated...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... beta-Lactamase Inhibitors …

Fruquintinib

Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Description: … [A262097] For the small-molecule approach, most earlier generations of VEGFR inhibitors such as [sunitinib ... Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity ... activity through monoclonal antibodies or blockage of VEGFR kinase activity through small-molecule inhibitors …

Axitinib

Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors …
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Tyrosine Kinase Inhibitors …

Human thrombin

Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting. Thrombin is a highly specific serine protease encoded by the F2 gene that transforms soluble fibrinogen into insoluble fibrin. This transformation mimics the final coagulation cascade step which involves the clotting mass...
Approved

Troglitazone

Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by pioglitazone and rosiglitazone.
Approved
Investigational
Withdrawn
Matched Categories: … BSEP/ABCB11 Inhibitors ... UGT1A6 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …

Elbasvir

Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in...
Approved
Matched Description: … inhibitors, another class of DAAs. ... [synthesis] The barrier to the development of resistance to NS5A inhibitors is lower than that of NS5B ... treatment failure with [ribavirin], [peginterferon alfa-2a], [peginterferon alfa-2b], or other NS3/4A inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …

Certolizumab pegol

Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated...
Approved
Matched Categories: … Tumor necrosis factor alpha (TNF-alpha) inhibitors …

Imipramine

Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts...
Approved
Matched Description: … TCAs are potent inhibitors of serotonin and norepinephrine reuptake. ... Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake …
Matched Categories: … OCT2 Inhibitors ... Adrenergic Uptake Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors …

Vardenafil

Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the...
Approved
Matched Description: … PDE5 inhibitors, such as vardenafil, inhibit the degradation of cGMP and allow increased blood flow into ... Although other PDE5 inhibitors such as [sildenafil] and [tadalafil] have been associated with rare cases …
Matched Categories: … Enzyme Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Phosphodiesterase Inhibitors …

Lopinavir

Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with ritonavir - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to lopinavir's poor oral bioavailability...
Approved
Matched Description: … [L11163] Like many other protease inhibitors (e.g. …
Matched Categories: … Enzyme Inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... Protease Inhibitors ... HIV Protease Inhibitors …

Cisatracurium

Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … This action is antagonized by acetylcholinesterase inhibitors such as neostigmine. …

Diflunisal

Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... UGT1A9 Inhibitors ... OAT1/SLC22A6 inhibitors ... Cyclooxygenase Inhibitors …

Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors …
Matched Categories: … BCRP/ABCG2 Inhibitors ... OCT1 inhibitors ... Enzyme Inhibitors ... UGT1A1 Inhibitors ... P-glycoprotein inhibitors …

Gilteritinib

Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Description: … Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors …
Matched Categories: … MATE inhibitors ... OCT1 inhibitors ... Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... MATE 1 Inhibitors …

Rosuvastatin

Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications...
Approved
Matched Categories: … Enzyme Inhibitors ... OAT3/SLC22A8 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …

Mobocertinib

Mobocertinib is a kinase inhibitor targeted against human epidermal growth factor receptor (EGFR). It is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the EGFR gene, which are typically associated with a poorer prognosis (as compared to "classical" EGFR mutants...
Approved
Investigational
Matched Description: … classical" _EGFR_ mutants causing NSCLC) and are associated with resistance to standard targeted EGFR inhibitors …
Matched Categories: … Enzyme Inhibitors ... BCRP/ABCG2 Inhibitors ... P-glycoprotein inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors …

Damoctocog alfa pegol

In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval. In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized. Also known as, BAY94-9027,...
Approved
Investigational
Displaying drugs 26 - 50 of 2428 in total